Quantellect · Analysts · Analyst Profile
Analyst rating accuracy & track record
Matthew Keller does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 IFRXInflaRx N.V. | Buy | $6.00 | Sep 2025 | +4.4% | Miss |
 GYREGyre Therapeutics Inc. | Buy | $18.00 | Aug 2025 | −46.3% | Miss |
 PHIOPhio Pharmaceuticals Corp | Buy | $14.00 | Aug 2025 | −75.2% | Miss |
 ACXPAcurx Pharmaceuticals LLC | Buy | $31.00 | Aug 2025 | −95.4% | Miss |
Prev1Next
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.